Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
First Investment: 2019
Current-day drug discovery is inefficient because the focus on molecular targets misses the underlying cellular- and tissue-level dynamics of disease. AI Vivo’s Organome technology ranks drug candidates based on their phenotypic effects at the tissue level. In 2020 the company’s platform correctly predicted that dexamethasone, a commonly prescribed steroid, would save the lives of Covid-19 patients 10 weeks before researchers publicized this outcome.
Explore Companies
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules